Brokerages Set RAPT Therapeutics, Inc. (NASDAQ:RAPT) PT at $9.56

Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) have been assigned an average recommendation of “Hold” from the thirteen brokerages that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $9.56.

Several analysts have recently commented on the company. JPMorgan Chase & Co. lowered RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a report on Monday, November 11th. Piper Sandler cut RAPT Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $8.00 to $2.00 in a research note on Monday, November 11th. HC Wainwright raised RAPT Therapeutics from a “neutral” rating to a “buy” rating and set a $10.00 price target for the company in a report on Thursday, December 26th. Wells Fargo & Company cut their price objective on shares of RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating on the stock in a report on Tuesday, November 12th. Finally, Stifel Nicolaus reiterated a “hold” rating and issued a $2.00 target price (down from $7.00) on shares of RAPT Therapeutics in a research note on Wednesday, November 13th.

RAPT Therapeutics Stock Performance

RAPT Therapeutics stock opened at $1.14 on Wednesday. RAPT Therapeutics has a 12-month low of $0.79 and a 12-month high of $27.35. The firm has a 50-day moving average price of $1.26 and a 200-day moving average price of $1.84. The firm has a market capitalization of $39.85 million and a PE ratio of -0.41.

RAPT Therapeutics (NASDAQ:RAPT) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.09. As a group, sell-side analysts predict that RAPT Therapeutics will post -2.43 earnings per share for the current fiscal year.

Institutional Trading of RAPT Therapeutics

A number of hedge funds have recently made changes to their positions in RAPT. Readystate Asset Management LP bought a new position in RAPT Therapeutics during the 3rd quarter valued at $36,000. JPMorgan Chase & Co. grew its position in shares of RAPT Therapeutics by 298.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock worth $34,000 after acquiring an additional 25,130 shares in the last quarter. Barclays PLC increased its holdings in shares of RAPT Therapeutics by 277.2% in the 3rd quarter. Barclays PLC now owns 39,729 shares of the company’s stock valued at $79,000 after acquiring an additional 29,195 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of RAPT Therapeutics during the 2nd quarter valued at approximately $108,000. Finally, SG Americas Securities LLC lifted its stake in RAPT Therapeutics by 401.9% during the fourth quarter. SG Americas Securities LLC now owns 53,244 shares of the company’s stock worth $84,000 after purchasing an additional 42,636 shares during the last quarter. Hedge funds and other institutional investors own 99.09% of the company’s stock.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.